Insulin Therapy
Insulin therapy is a hormone-replacement treatment in which exogenous insulin is administered to lower and stabilize blood glucose in people whose endogenous insulin secretion or action is insufficient.
Insulin therapy is a hormone-replacement treatment in which exogenous insulin is administered to lower and stabilize blood glucose in people whose endogenous insulin secretion or action is insufficient. In clinical use since the early 1920s, it is the indispensable, lifelong treatment for type 1 diabetes, where autoimmune destruction of pancreatic beta cells abolishes endogenous secretion, and it is added in advanced type 2 diabetes when lifestyle measures, metformin, SGLT2 inhibitors, GLP-1 receptor agonists such as semaglutide, and other non-insulin agents no longer maintain adequate glycemic control. It is also used to manage drug-induced hyperglycemia, including the hyperglycemia caused by Phosphatidylinositol 3-kinase (PI3K) inhibitors such as alpelisib in oncology. Because the therapeutic goal is to reproduce a physiological secretion pattern, formulations are grouped by kinetics: rapid-acting analogs given as mealtime boluses or delivered by pump, and intermediate- or long-acting basal preparations. Dosing is titrated against glycemic monitoring, and the main treatment-limiting harm is hypoglycemia, alongside weight gain.
Therapeutically administered insulin acts through the same pathway as the native hormone, binding the insulin receptor — a receptor tyrosine kinase — and initiating signaling that drives glucose uptake into skeletal muscle and adipose tissue, suppresses hepatic glucose production, and promotes glycogen, lipid, and protein synthesis. In obesity-related type 2 diabetes this signaling is blunted by insulin resistance, characterized by reduced insulin-stimulated glucose uptake, intramuscular triacylglycerol accumulation, and mitochondrial dysfunction; resistance interacts with adipose-derived signals such as leptin and with cellular energy sensing through AMP-activated protein kinase, and progression to diabetes depends on whether beta-cell secretory compensation keeps pace with falling sensitivity. insulin signaling also has non-metabolic consequences: it shapes CD4+ effector memory T-cell metabolism and phenotype through epigenetic mechanisms, a link observed in autoimmune settings such as rheumatoid arthritis, and hyperinsulinemia is associated with an altered inflammatory milieu including Interleukin-6 (IL-6) and C-C motif chemokine ligand 2. Current pharmaceutical development focuses on automated (closed-loop) insulin delivery systems paired with continuous glucose monitoring, on formulation stability and oligomerization behavior, which govern absorption kinetics, and on alternative routes — oral, sublingual, transdermal, and ocular — together with glucose-responsive delivery systems intended to release insulin in proportion to ambient glucose.
Where the papers sit
8 papers from the last 6 months study Insulin Therapy directly · updated from PubMed 16 Nov 2026
Study type 1 clinical trial · 4 human data · 2 preclinical · 1 unclassified
Themes one subject
Those 8 are all about one subject.
-
Insulin and Diabetes Biology
Insulin research here spans delivery systems, secretion, glucose regulation, diabetes risk and therapeutic protein quality. Human studies emphasize early insulin-secretory defects, postprandial metabolic heterogeneity and polygenic susceptibility to type 2 diabetes. Clinical analyses also track alpelisib-induced hyperglycemia and the budget impact of advanced delivery for type 1 diabetes. Mechanistic work links vagal nitric oxide signaling to insulin release and insulin exposure to IL7R+ memory phenotypes in PD1+ T cells, leaving the cluster broad rather than directional.
Papers
The 8 papers from the last 6 months that study Insulin Therapy directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Insulin and Diabetes Biology (8)
- Budget Impact of Advanced Insulin Delivery Systems for the Management of Type 1 Diabetes. Diabetes technology & therapeutics · 1 Jul 2026 PMID 42381171
- Simple Hydrodynamic Molecular Weight Model for Rapid Assessment of Therapeutic Protein Oligomerization States in Formulation. The AAPS journal · 29 Jun 2026 PMID 42373916
- Global and Partitioned Polygenic Risk Scores: Associations With Pathophysiology and Incidence of Type 2 Diabetes in People With Prediabetes. Diabetes · 22 Jun 2026 PMID 42330299
- Vagal activation inhibits insulin release through neuronal nitric oxide synthase in obese male mice. Science signaling · 26 May 2026 PMID 42189938
- Insulin enables acquisition of the IL7R+ memory phenotype in PD1+ T cells in RA tissues. Cell death & disease · 25 May 2026 PMID 42185247
- The 1-hour plasma glucose as a specific marker for early-phase insulin secretory defects in young adults with obesity. Diabetes research and clinical practice · 25 May 2026 PMID 42184890
- Heterogeneity in postprandial glucose-insulin and triacylglycerol dynamics and associations with plasma metabolome and body composition in obesity. American journal of physiology. Endocrinology and metabolism · 21 May 2026 PMID 42166654
- Assessment of alpelisib-induced hyperglycemia in a real-world setting: A nationwide claims data analysis. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 20 May 2026 PMID 42159385
By study type
Clinical trials (1)
- Global and Partitioned Polygenic Risk Scores: Associations With Pathophysiology and Incidence of Type 2 Diabetes in People With Prediabetes. Diabetes · 22 Jun 2026 PMID 42330299
Human data, design not indexed (4)
- Budget Impact of Advanced Insulin Delivery Systems for the Management of Type 1 Diabetes. Diabetes technology & therapeutics · 1 Jul 2026 PMID 42381171
- Insulin enables acquisition of the IL7R+ memory phenotype in PD1+ T cells in RA tissues. Cell death & disease · 25 May 2026 PMID 42185247
- The 1-hour plasma glucose as a specific marker for early-phase insulin secretory defects in young adults with obesity. Diabetes research and clinical practice · 25 May 2026 PMID 42184890
- Heterogeneity in postprandial glucose-insulin and triacylglycerol dynamics and associations with plasma metabolome and body composition in obesity. American journal of physiology. Endocrinology and metabolism · 21 May 2026 PMID 42166654
Preclinical: animal, cell and lab studies (2)
- Simple Hydrodynamic Molecular Weight Model for Rapid Assessment of Therapeutic Protein Oligomerization States in Formulation. The AAPS journal · 29 Jun 2026 PMID 42373916
- Vagal activation inhibits insulin release through neuronal nitric oxide synthase in obese male mice. Science signaling · 26 May 2026 PMID 42189938
Unclassified: not yet indexed with MeSH (1)
- Assessment of alpelisib-induced hyperglycemia in a real-world setting: A nationwide claims data analysis. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 20 May 2026 PMID 42159385
Written from 8 PubMed abstracts, each one listed by PMID above. Published: 2026-06-13. Last written: 2026-08-26 by GPT. Reviewed by a human editor on 2026-07-23. Drafted by language models from published abstracts; not medical advice.